Alogliptin benzoate for management of type 2 diabetes

Yoshifumi Saisho

研究成果: Review article査読

18 被引用数 (Scopus)


Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well tolerated because of their low risk of hypoglycemia and other adverse events. Moreover, with their potential to improve beta cell function, a core defect of type 2 diabetes, DPP-4 inhibitors are becoming a major component of treatment of type 2 diabetes. Alogliptin benzoate is a newly developed, highly selective DPP-4 inhibitor which has been approved in many countries throughout the world. Once-daily administration of alogliptin as either monotherapy or combination therapy with other oral antidiabetic drugs or insulin has a potent glucose-lowering effect which is similar to that of other DPP-4 inhibitors, with a low risk of hypoglycemia and weight gain. The cardiovascular safety of this drug has been confirmed in a recent randomized controlled trial. This review summarizes the efficacy and safety of alogliptin, and discusses the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

ジャーナルVascular Health and Risk Management
出版ステータスPublished - 2015 4月 10

ASJC Scopus subject areas

  • 内分泌学、糖尿病および代謝内科学
  • 血液学
  • 公衆衛生学、環境および労働衛生
  • 循環器および心血管医学
  • 薬理学(医学)


「Alogliptin benzoate for management of type 2 diabetes」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。